Home Cardiac Sodium Channel Diseases
Article
Licensed
Unlicensed Requires Authentication

Cardiac Sodium Channel Diseases

  • Carlo Napolitano , Ilaria Rivolta and Silvia G. Priori
Published/Copyright: June 1, 2005
Become an author with De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 41 Issue 4

Abstract

In the last few years, a very active line of research took place after the first identification of SCN5A mutations associated with an inherited form of cardiac arrhythmias and sudden death, the LQT3 variant of the long QT syndrome. Subsequently, two allelic diseases additional to LQT3 were shown to be due to mutations in the same gene, the Brugada syndrome (BrS) and the Lev-Lenegre syndrome (progressive cardiac conduction defect). Genotype-phenotype correlation and in vitro expression studies provide evidence that structure-function relationships of the SCN5A protein are much more complex than initially anticipated. The biophysical characterization of the sodium channel defects associated with different phenotypes and the genotype-phenotype correlation studies brought to the attention of the scientific community a plethora of mechanisms by which even a single amino acid substitution may remarkably affect cardiac excitability. Finally, the evidence of patients harboring an SCN5A mutation and overlapping clinical presentations creates a need for a revision of the traditional classification of the above mentioned diseases. It is now appropriate to consider the “sodium channel syndrome” as a unique clinical entity that may manifest itself with a spectrum of possible phenotypes.

:
Published Online: 2005-06-01
Published in Print: 2003-04-25

Copyright © 2003 by Walter de Gruyter GmbH & Co. KG

Articles in the same Issue

  1. First Santorini Conference: From Genetic Variations to Risk Prediction and Pharmacogenomics
  2. Pharmacogenetics and Pharmacogenomics in Drug Discovery and Development: An Overview
  3. Regulatory Gene Mutations Affecting Apolipoprotein Gene Expression: Functions and Regulatory Behavior of Known Genes May Guide Future Pharmacogenomic Approaches to Therapy
  4. The Proteome: Anno Domini 2002
  5. Cardiac Sodium Channel Diseases
  6. Haemophilia B: From Molecular Diagnosis to Gene Therapy
  7. The Use of Denaturing High-Performance Liquid Chromatography (DHPLC) for the Analysis of Genetic Variations: Impact for Diagnostics and Pharmacogenetics
  8. Molecular Diagnostics by Microelectronic Microchips
  9. Molecular Beacons as Diagnostic Tools: Technology and Applications
  10. Electrochemical DNA Sensor for Detection of Single Nucleotide Polymorphisms
  11. Comparison of Standard PCR and the LightCycler® Technique to Determine the Thrombophilic Mutations: An Efficiency and Cost Study
  12. Impact of Purified Water Quality on Molecular Biology Experiments
  13. Which Are the best Tools for Specific Clinical Application (Chips, Multiplex, Mass Spec Profile, etc.)?
  14. Genetic Variations Observed in Arterial and Venous Thromboembolism – Relevance for Therapy, Risk Prevention and Prognosis
  15. The TNF- α Gene NcoI Polymorphism at Position –308 of the Promoter Influences Insulin Resistance, and Increases Serum Triglycerides after Postprandial Lipaemia in Familiar Obesity
  16. The –308 G/A Tumor Necrosis Factor-α Gene Dimorphism: A Risk Factor for Unstable Angina
  17. The Apolipoprotein AV Gene and Diurnal Triglyceridaemia in Normolipidaemic Subjects
  18. Left Ventricular Size, Mass and Function in Relation to Angiotensin-Converting Enzyme Gene and Angiotensin-II Type 1 Receptor Gene Polymorphisms in Patients with Coronary Artery Disease
  19. Analysis of Multiple Single Nucleotide Polymorphisms of Candidate Genes Related to Coronary Heart Disease Susceptibility by Using Support Vector Machines
  20. PON1-192 Phenotype and Genotype Assessments in 918 Subjects of the Stanislas Cohort Study
  21. Lipoprotein Lipase Gene Polymorphisms in Croatian Patients with Coronary Artery Disease
  22. Homocysteine, Methylenetetrahydrofolate Reductase C677T Polymorphism and the B-Vitamins: A Facet of Nature-Nurture Interplay
  23. Which, and How Limited Number of Polymorphisms Should Be Selected per Disease, Risk Assessment, Health Profile or Biological System?
  24. Ethical Issues: Should We Give the Predictive Genetic Profile to the Citizens?
  25. Pharmacogenetics and Responders to a Therapy: Theoretical Background and Practical Problems
  26. Pharmacogenetics of Drug Metabolising Enzymes: Importance for Personalised Medicine
  27. Pharmacogenomics and Pharmacogenetics of Cholesterol-Lowering Therapy
  28. Pharmacogenomics of Drugs Affecting the Cardiovascular System
  29. Allele Frequencies for Glutathione S-Transferase and N-Acetyltransferase 2 Differ in African Population Groups and May Be Associated With Oesophageal Cancer or Tuberculosis Incidence
  30. CYP3A4*1B and NAT2*14 Alleles in a Native African Population
  31. Pharmacogenetics: From Bench to Bedside
  32. Meetings and Awards
Downloaded on 10.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2003.066/html
Scroll to top button